Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Tables)

v3.22.2.2
Stockholders' Equity (Tables)
9 Months Ended
Sep. 30, 2022
Stockholders' Equity  
Summary of restricted stock award activity

Weighted Average

Number of

Grant Date Fair

    

Shares

    

Value  

Non-vested at December 31, 2021

4,512,701

$

3.35

Granted

1,594,214

2.00

Forfeited

(84,000)

2.75

Vested

(2,087,710)

3.68

Non-vested at September 30, 2022

3,935,205

$

2.64

Summary of restricted stock units activity

The following table summarizes restricted stock units activity for the nine months ended September 30, 2022:

    

    

Weighted Average

Number of

Grant Date Fair

Shares

Value

Non-vested at December 31, 2021

 

$

Granted

 

850,000

 

1.05

Non-vested at September 30, 2022

 

850,000

$

1.05

Summary of stock option award activity

Weighted Average 

Remaining

Weighted Average 

 Contractual Life

    

Stock Options 

    

Exercise Price

    

(in years)

Outstanding as of December 31, 2021

270,000

$

3.14

7.44

Granted

40,000

1.42

Forfeited

(40,000)

1.42

Outstanding as of September 30, 2022

270,000

$

3.14

6.69

Vested and exercisable as of September 30, 2022

155,000

$

2.31

7.14

Summary of stock options assumptions used

For the Nine Months Ended September 30, 

 

    

2022

    

2021

 

Risk-free interest rate

 

1.30

%  

1.04% - 1.50

%

Expected dividend yield

 

Expected term in years

 

10.0

10.0

Expected volatility

 

100.65

%  

100.65% - 102.71

%

Summary of warrant activities

Weighted Average 

Remaining

Weighted Average 

Contractual Life

    

Warrants 

    

Exercise Price 

    

(in years)

Outstanding as of December 31, 2021

12,493

$

0.00

3.83

Exercised

Outstanding as of September 30, 2022

12,493

$

0.00

3.08

Summary of stock-based compensation expense

The following table summarizes stock-based compensation expense for the three and nine months ended September 30, 2022 and 2021 ($ in thousands):

For the three months ended September 30, 

For the nine months ended September 30, 

    

2022

    

2021

    

2022

    

2021

Research and development

$

276

$

161

$

752

$

480

General and administrative

 

505

 

618

 

1,533

 

1,839

Total stock-based compensation expense

$

781

$

779

$

2,285

$

2,319